Person: İLHAN, MAHMUT MUZAFFER
19 results
Search Results
Now showing 1 - 10 of 19
Publication Metadata only Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?(2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.Publication Metadata only A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus(2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRULPurpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.Publication Metadata only Tip 1 Diabetes Mellituslu Obez Olguda Bariyatrik Cerrahinin Etkisi(2017-05-03) YASİN, AYŞE İREM; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRULPublication Metadata only Hipoglisemi sendromunun fotopletismografi ve elektriksel deri iletkenliği sinyalleri üzerindeki etkisi(2014-09-25) OKKESİM, ŞÜKRÜ; ÇELİK, GAMZE; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCANPublication Metadata only Bariatrik Cerrahi Planlanan Morbid Obez Bireylerde Beden Algisi, Benlik Saygisi Ve Cinselhayat Kalitesinin İncelenmesi(2016-05-15) EKİNCİ, ESRA; BIKMAZ, PERVİN SEVDA; EKİNCİ, İSKENDER; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULPublication Metadata only Hipofizer ve adrenal cushing sendromu birlikteliği(2014-05-21) KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; YASİN ÇETİN, AYŞE İREM; HAMDARD, JAMSHID; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFERPublication Metadata only Atipik Subakut Tiroidit Olgusu(2017-05-03) KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; YASİN, AYŞE İREM; DAE, SHUTE AILIA; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; DAE, SHUTE AıLıA; TAŞAN, ERTUĞRULPublication Metadata only Diyabette kür sekonder sebeplerin önemi(2014-03-15) KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; YASİN ÇETİN, AYŞE İREM; YAY, ADNAN; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFERPublication Metadata only Cushing-s syndrome in obese patients with type 2 diabetes: A single center screening study(2017-03-01) Karaman, Ozcan; ZUHUR, Sayid Shafi; CIL, Esra; OZDERYA, Aysenur; OZTURK, Feyza Yener; Ilhan, Muzaffer; ALTUNTAS, Yuksel; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFERThe frequency of Cushing-s syndrome (CS) in obese patients was not properly determined and the studies focused on the frequency of occult CS and the possible improvement of diabetes and obesity with treatment of CS are needed. In this study, we aimed to investigate the frequency of CS in obese patients with type 2 diabetes. The study enrolled with 200 obese (body mass index (BMI) > 30 kg/m(2)), type 2 diabetes patients between 2009 and 2011 in Sisli Etfal Training and Research Hospital, Turkey. Twenty-eight males and 172 females were recruited to the study. Mean age of the study group was 51.7 +/- 8.5. Nineteen patients (9.5 %) failed to suppress cortisol levels less than 1.8 mu g/dL after a 1-mg overnight dexamethasone suppression test (ODST) and these patients proceeded to have a 2-day 2-mg low-dose dexamethasone suppression test. After further screening, three (%1.5) patients were diagnosed with CS in our study. Among the three patients diagnosed with CS, the tumor was located in the pituitary gland in two patients. The present study revealed that the frequency of Cushing-s syndrome in obese and diabetic patients were 1.5 %, which was much higher than the general population. Occult CS should take into account as an exacerbating factor for diabetes and screening for CS should be considered in poorly controlled diabetic patients.Publication Metadata only Obezlerde bariatrik cerrahi sonrası kilo vermenin anti müllerian hormon düzeyi üzerine etkisi(2015-05-06) BÜYÜKKABA, MİTAT; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; TURAN, SAİME; YAY, ADNAN; ZEYBEK, ŞAKİR ÜMİT; YAYLIM, İLHAN; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER